<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-150717</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Prediction of biochemical recurrence after radical prostatectomy. New tool for selecting candidates for adjuvant radiation therapy</dc:title>
<dc:description xml:lang="en">Objective: To design a risk summation to select patients for adjuvant radiation therapy after prostatectomy. Materials and method: A retrospective study was conducted on 629 patients with localised prostate cancer (pN0&#150;pNx) who were treated with prostatectomy and with a prostate-specific antigen (PSA) value &lt;0.2 ng/mL at 2&#150;3 months. Biochemical recurrence was defined as a PSA &gt;0.4 ng/mL. A multivariate Cox regression analysis was performed. A score (0&#150;2) was assigned according to the hazard ratio of the significant variables. The score summation defined the risk summation. Results: A total of 19.7% of the patients were pT3, 24.2% had a Gleason score &amp;#8805;8, and 26.3% had positive surgical margins. The median follow-up was 82 months. Some 26.6% of the patients experienced biochemical recurrence. The identified prognostic variables independent of biochemical recurrence were a Gleason score =7 (4 + 3) (HR, 2.01; P=.008), a Gleason score &amp;#8805;8 (HR, 3.07; P &lt;.001), a pT3b stage (HR, 1.93; p=.008) and a positive surgical margin (HR, 2.20; P&lt;.001). We assigned 0 points to patients without risk prognosis variables; 1 point to patients with Gleason scores =7 (4 + 3), pT3b or positive surgical margins; and 2 points to patients with Gleason scores &amp;#8805;8. The patients with a risk summation &amp;#8804;2 had &gt;50% survival free of biochemical recurrence at 5 and 8 years. In contrast, the patients with a risk summation &amp;#8805;3 had &lt;44% survival free of biochemical recurrence. Conclusion: The patients with a risk summation &amp;#8804;2 did not benefit from adjuvant radiation therapy, while the patients with a risk summation &amp;#8805;3 might benefit from adjuvant radiation therapy (AU)</dc:description>
<dc:creator>Ogaya Pinies, G</dc:creator>
<dc:creator>Ramírez Martín, D</dc:creator>
<dc:creator>Molina Escudero, R</dc:creator>
<dc:creator>Herranz Amo, F</dc:creator>
<dc:creator>Hernández-Fernández, C</dc:creator>
<dc:creator>Verdú-Tartajo, F</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Diseñar un sumatorio de riesgo para la selección de pacientes para radioterapia adyuvante después de prostatectomía. Material y método: Estudio retrospectivo de 629 pacientes con cáncer de próstata localizado y pN0-pNx tratados con prostatectomía y con un PSA a los 2-3 meses &lt; 0,2 ng/ml. Recidiva bioquímica si PSA &gt; 0,4 ng/ml. Análisis multivariante mediante regresión de Cox. Asignación de puntuación (0-2) en función del HR de las variables significativas. El sumatorio de las puntuaciones definió el sumatorio de riesgo. Resultados: El 19,7% pT3, 24,2% Gleason &amp;#8805; 8 y el 26,3% de márgenes quirúrgicos positivos. Mediana de seguimiento de 82 meses. Recidiva bioquímica el 26,6%. El Gleason = 7 (4 + 3) (HR = 2,01, p = 0,008), el Gleason &amp;#8805; 8 (HR = 3,07, p &lt; 0,001), el estadio pT3b (HR = 1,93, p = 0,008) y el margen quirúrgico positivo (HR = 2,20, p &lt; 0,001) se identificaron como variables pronosticas independientes de recidiva bioquímica. Se asignó 0 puntos a los pacientes sin variables pronósticas de riesgo, un punto a los pacientes con Gleason = 7 (4 + 3), pT3b o márgenes quirúrgicos positivos y 2 puntos si Gleason &amp;#8805; 8. Los pacientes con un sumatorio de riesgo &amp;#8804; 2 tuvieron una supervivencia libre de recidiva bioquímica a los 5 y 8 años superior al 50%, en cambio, los pacientes con un sumatorio de riesgo &amp;#8805; 3 tuvieron una supervivencia libre de recidiva bioquímica inferior al 44%. Conclusión: Los pacientes con un sumatorio de riesgo &amp;#8804; 2 no se beneficiarían de radioterapia adyuvante, mientras que los pacientes con un sumatorio de riesgo &amp;#8805; 3 pudieran beneficiarse de radioterapia adyuvante (AU)</dc:description>
<dc:source>Actas Urol Esp;40(2): 82-87, mar. 2016. tab, graf</dc:source>
<dc:identifier>ibc-150717</dc:identifier>
<dc:title xml:lang="es">Predicción de recidiva bioquímica tras prostatectomía radical. Nueva herramienta para la selección de candidatos a radioterapia adyuvante</dc:title>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d12314^s22083</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12314^s22045</dc:subject>
<dc:subject>^d12314^s22066</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12314^s22047</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d11914^s22011</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d11914^s22054</dc:subject>
<dc:subject>^d9557^s22047</dc:subject>
<dc:subject>^d11914^s22067</dc:subject>
<dc:subject>^d9557^s22067</dc:subject>
<dc:subject>^d9557^s22016</dc:subject>
<dc:subject>^d9557^s22054</dc:subject>
<dc:subject>^d11914^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201603</dc:date>
</metadata>
</record>
</ibecs-document>
